ISO 11608 Standards for Pen Injectors – A Comprehensive Overview
Introduction
Needle-based injection systems (NISs) represent the primary method for drug delivery worldwide, with an estimated 16 billion injections administered globally each year. From insulin pens for diabetes management to advanced autoinjectors for biologic therapies, these devices have become indispensable tools in modern healthcare. Ensuring their safety, reliability, and accuracy is therefore paramount—not only to prevent the transmission of bloodborne pathogens and avoid tissue damage, but to guarantee accurate medication delivery for life-saving, self-administered therapies.
Since the publication of ISO 11608-1: Pen Injectors for Medical Use – Requirements and Test Methods in 2000, the ISO 11608 series has set the global standard for how needle-based injection devices should be designed, verified, and manufactured. In 2022, the series underwent its most comprehensive update in a decade, introducing new concepts, restructuring content, and expanding coverage to emerging device categories such as On-Body Delivery Systems (OBDS) and electronic NISs.
For pharmaceutical manufacturers and packaging professionals, understanding and complying with ISO 11608 is not merely a regulatory checkbox—it is a strategic imperative that impacts product development timelines, market access, patient safety, and commercial success. This comprehensive overview provides a detailed examination of the ISO 11608 series, its key requirements, recent updates, and practical implications for pen injector manufacturers.
At Vialab Pharmaceutical Packaging Co., Ltd. , we specialize in the design and manufacture of high-quality drug delivery and packaging components—from injection pens (disposable and reusable) to glass vials, sterile vials, and aluminum caps—all engineered to meet strict pharmaceutical standards. Our commitment to ISO/GMP compliance and rigorous quality control ensures that every component we produce aligns with the requirements of the ISO 11608 series and supports our global healthcare partners in achieving regulatory success.
1. What is ISO 11608?
ISO 11608 is the international standard that regulates Needle-Based Injection Systems (NISs) used for medical drug delivery. The standard specifies performance, design, testing, and safety requirements to ensure that injection devices deliver accurate doses in a reliable and user-safe manner.
An NIS is defined as an “injection system intended for parenteral administration of medicinal products using a needle or cannula and a multi-dose or single-dose container”. This broad definition encompasses a wide range of devices including syringes, autoinjectors, and pen injectors, designed to deliver drugs subcutaneously, intramuscularly, or intradermally.
The ISO 11608 series is developed under the remit of ISO Technical Committee 84 (ISO TC84) , a committee focused on defining requirements and test methods to ensure safe and effective devices are made available to the widest number of people. The standard is drafted with international relevance in mind, written in language sufficiently broad to facilitate global application while accounting for both US and European regulatory frameworks.
2. The ISO 11608 Series: Structure and Scope
The ISO 11608 family consists of seven parts, each addressing a specific aspect of needle-based injection systems:
| Part | Title | Scope |
|---|---|---|
| ISO 11608-1 | Needle-based injection systems | General requirements and test methods (the “parent” standard) |
| ISO 11608-2 | Double-ended pen needles | Requirements for single-use, sterile double-ended needles |
| ISO 11608-3 | Containers and integrated fluid paths | Design verification of containers and fluid pathways |
| ISO 11608-4 | Systems containing electronics | Electronic and electromechanical NIS requirements |
| ISO 11608-5 | Automated functions | Requirements for automated functions in NIS-AUTO |
| ISO 11608-6 | On-body delivery systems | OBDS requirements and test methods |
| ISO 11608-7 | Accessibility for visually impaired | Design guidance for visually impaired users |
For pen injector manufacturers, ISO 11608-1, 11608-2, and 11608-3 represent the core compliance focus. However, as devices become increasingly sophisticated with electronic components and automated functions, Parts 4 and 5 are becoming increasingly relevant.
ISO 11608-1: The Parent Standard
ISO 11608-1 serves as the ‘parent’ part—the fundamental section of the standard that establishes the requirements and test methods for all NIS devices covered by the entire standard. The current version, ISO 11608-1:2022, specifies requirements and test methods for NISs for single-patient use intended to deliver discrete volumes (bolus) of medicinal product, delivered through needles or soft cannulas for intradermal, subcutaneous, and/or intramuscular delivery.
The standard applies to NISs incorporating pre-filled or user-filled, replaceable or non-replaceable containers. However, it explicitly excludes stand-alone prefilled syringes defined by ISO 11040-8, NISs that provide continuous delivery (such as insulin patch pumps), and NISs with containers that can be refilled multiple times.
ISO 11608-2: Double-Ended Pen Needles
ISO 11608-2 specifies requirements and test methods for single-use, double-ended, sterile needles intended for use with NISs that fulfill the specifications of ISO 11608-1. This part covers critical aspects including flow rate through the needle, bond integrity between hub and needle tube, and functional compatibility of the system.
ISO 11608-3: Containers and Integrated Fluid Paths
ISO 11608-3 specifies requirements and test methods for design verification of containers and integrated fluid paths used with NISs according to ISO 11608-1. It is applicable to single and multi-dose containers, whether filled by the manufacturer (primary container closure) or by the end-user (reservoir), such as cartridges.
This part has been updated to include integrated fluid paths as well as finished containers, covering rigid needles, soft cannulas, and any fluid line connections.
ISO 11608-4: Electronic and Electromechanical Systems
ISO 11608-4 specifies requirements and test methods for needle-based injection systems containing electronics with or without software (NIS-Es) . These systems can be single-use or reusable and can be operated with or without electrical/conductive connections to other devices. Requirements relating to electronic devices such as EMC are now solely within ISO 11608-4, reflecting the increasing prevalence of connected and smart injection devices.
ISO 11608-5: Automated Functions
ISO 11608-5 specifies requirements and test methods for automated functions in NISs with automated functions (NIS-AUTO) . General requirements are provided for all automated functions, with specific requirements for functions including medicinal product preparation (e.g., reconstitution).
ISO 11608-6: On-Body Delivery Systems
ISO 11608-6, introduced in 2022, specifies requirements and test methods for On-Body Delivery Systems (OBDS) —needle-based injection systems for single-patient use intended for subcutaneous delivery. OBDS are distinct from infusion pumps or insulin patch pumps: in infusion pumps, the rate of delivery is critical to clinical function, whereas an OBDS delivers a discrete volume (bolus) in a time governed by tolerability and convenience.
ISO 11608-7: Accessibility for Visually Impaired Users
ISO 11608-7, published in 2016, specifies particular requirements to make NISs accessible for persons with visual impairments. It addresses the needs of persons with all levels of visual limitations, including low, moderate, or severe visual impairment; legal, functional, or total blindness; and color vision deficiencies. The standard includes the requirement to provide information in visual formats that can be perceived and understood by people with moderate visual impairment, as well as in non-visual formats.
3. Key Updates in the 2022 Revision
The 2022 revision of the ISO 11608 series represented the most comprehensive update since 2014. Key changes include:
Introduction of “Primary Functions”
One of the most significant changes in ISO 11608-1:2022 is the introduction of the term “primary functions,” which replaces the term “essential performance”. A primary function is defined as:
A “function or operation of the needle-based injection system which, if it does not perform to specifications during use, would directly result in a failure to accurately deliver the medicinal product via the correct route and/or directly result in unacceptable harm to the patient”
When it comes to verification of requirements identified as primary functions, the same approach and assessment criteria set out for dose accuracy should be applied. The 2022 version explicitly states that risk management tools should be applied to the primary functions defined above.
Restructuring and Content Realignment
The revision involved relocating some content previously in ISO 11608-1 to other standards in the family. For example, requirements relating to electronic devices such as EMC are now solely within ISO 11608-4. This restructuring ensures better alignment across the various parts, reduces duplication, and ensures every potential NIS is addressed.
Expansion of Scope
- ISO 11608-3 has been updated to include integrated fluid paths as well as finished containers
- ISO 11608-4 has been expanded to cover a wider range of functions with electronic NISs
- ISO 11608-6 was introduced to address On-Body Delivery Systems
Introduction of “Functional Stability”
The revision introduces the concept of functional stability, which expands testing regimens to simulate whole-life testing for reusable devices. This is particularly relevant for reusable pen injectors that must maintain performance over extended periods and thousands of cycles.
Enhanced Risk-Based Design Requirements
The design specification for the NIS must consider the impact and requirements of the medicinal product, and the guidance on risk-based design approaches has been expanded. While the 2014 version referenced ISO 14971 and IEC 62366 for Risk Management and Usability Engineering, these sections are expanded in the 2022 version.
4. Key Technical Requirements for Pen Injectors
To comply with ISO 11608, manufacturers must demonstrate that their devices consistently meet performance expectations throughout their intended lifecycle. The main criteria include:
Dose Accuracy
The injector must deliver precise and repeatable doses within allowable deviation limits. Testing must be conducted across different dose levels and environmental conditions. Dose accuracy testing includes:
- Testing under standard, cool, and warm atmospheres
- Testing after dry heat storage preconditioning
- Testing after cold storage preconditioning
- Last-dose accuracy testing for applicable system designations
Injection Force
The device must remain easy and safe for patients to operate. ISO 11608 sets limits on the force required to activate dose delivery. This is particularly critical for patients with limited dexterity, such as elderly individuals or those with arthritis.
Robustness and Reliability
Pen injectors must withstand drops, vibration, and mechanical stress during shipping, storage, and daily handling—without performance loss. Testing categories include drop tests, vibration, shock, and mechanical durability testing.
Needle and Cartridge Compatibility
The design must ensure secure needle attachment, leak-proof sealing, and compatibility with standard cartridges (typically 3 mL or 1.5 mL).
Human Factors and Usability
The design must minimize user error and ensure safe operation for patients of varying age, experience, and physical limitations. Human factors validation per IEC 62366 is a critical component of the compliance process.
5. Regulatory Recognition and Global Impact
FDA Recognition
The FDA increasingly uses ISO standards as part of its device review and approval process. For NISs, the FDA directly references the ISO 11608 series in its published guidance for injection devices. As of May 30, 2022, the FDA recognized ISO 11608-1:2022. Companies designing devices for the US market are highly recommended to demonstrate compliance with these recognized standards.
EMA and Global Recognition
EMA mandates compliance with EU Medical Device Regulation (MDR) and usability validation across diverse patient groups. ISO 11608 alignment supports approvals in major markets including the US, EU, UK, and Asia, often reducing regulatory review time.
Why Compliance Matters
Due to its global influence and visibility, it is becoming increasingly difficult for device manufacturers to enter the market without ISO 11608 compliance, especially in markets where competitors are doing so. For NIS manufacturers, compliance with ISO 11608 is essential for doing business globally.
6. Upcoming Amendments: 2025–2026
The ISO 11608 series continues to evolve. Several amendments are currently in development:
- ISO 11608-1:2022/Amd 1:2026: An amendment to the parent standard, currently under publication
- ISO 11608-3:2022/Amd 1:2026: An amendment to Part 3 addressing containers and integrated fluid paths
- ISO 11608-3:2022/DAM 1:2025: A draft amendment to Part 3, with a publication date of November 2025
These amendments reflect the ongoing evolution of the industry and the need to keep standards current with technological developments.
7. Practical Recommendations for Manufacturers
To achieve ISO 11608 compliance effectively:
- Integrate compliance early in product design, not only during final testing
- Conduct usability studies with real patient groups, especially for chronic diseases
- Establish Quality Management Systems (QMS) aligned with ISO 13485 for device manufacturing
- Choose material and component suppliers with proven medical-grade validation and compliance track records
- Document all test methods, validation, and results as part of your technical compliance file
Conclusion
The ISO 11608 series represents the cornerstone of quality and safety for needle-based injection systems worldwide. From the general requirements of Part 1 to the specialized provisions of Parts 2 through 7, the standard provides a comprehensive framework for ensuring that pen injectors and related devices deliver accurate doses reliably and safely.
The 2022 revision brought significant improvements—introducing the concept of primary functions, expanding coverage to emerging device categories, and enhancing risk-based design requirements. With ongoing amendments scheduled for 2025–2026, the standard continues to evolve alongside the industry it serves.
For pharmaceutical manufacturers and packaging partners, ISO 11608 compliance is not optional—it is a prerequisite for global market access, regulatory approval, and patient trust.
At Vialab Pharmaceutical Packaging Co., Ltd. , we are committed to supporting our partners through every stage of the compliance journey. From injection pens (disposable and reusable) and glass vials to sterile vials and aluminum caps, every component we manufacture is designed with ISO/GMP compliance and rigorous quality control at its core. Our advanced production lines and cleanroom facilities ensure consistent quality, integrity, and compliance for global healthcare partners.
Whether you are developing a new pen injector, transitioning between disposable and reusable platforms, or seeking to enhance your existing product line, our team of packaging experts is ready to provide the technical guidance and manufacturing excellence you need to succeed in this rapidly evolving regulatory landscape.
Contact Vialab Pharmaceutical Packaging Co., Ltd. today to discuss your pen injector packaging requirements and discover how our precision pharmaceutical packaging solutions can support your ISO 11608 compliance journey.